In This Section

Agenda*

The SNMMI Therapeutics Conference has been developed to educate nuclear medicine physicians, technologists, hospital administrators, nurses, oncologists, and patients about the “how-to's” of establishing a nuclear medicine therapy program in their institution. This meeting will reach an audience that does not normally attend SNMMI meetings and who may not have the knowledge or resources of setting up or providing theranostic agents for their patients.

Friday, October 25

1:00–2:00 pm

Registration and Refreshments with Exhibitors

2:00–2:10 pm

Welcome and Program Overview

Phillip Koo, MD, Banner MD Anderson Cancer Center

2:10–2:30 pm

Reintroducing Therapeutics: Nuclear Medicine Physician Leading Patient Care Team

Dan Pryma, MD, University of Pennsylvania

2:30–3:15 pm

Establishing Your Practice in Systemic Radiation Therapy in Theranostics Practice

Sandy McEwan, MD, Ipsen Radiopharmaceuticals

3:15–3:30 pm

The Role of Technologists in Theranostics Practice

Audrey Davis, CNMT, Banner MD Anderson Cancer Center

3:30–3:40 pm

Question and Answer

3:40–4:00 pm

Operationalizing a 177Lu-Dotatate Clinic

Jennifer Kwak, MD, University of Colorado

4:00–4:15 pm

Break

4:15–4:35 pm

Operationalizing Your Practice For 223Ra-Dichloride

Phillip Koo, MD, Banner MD Anderson Cancer Center

4:35–4:55 pm

Operationalizing Your Practice For 177Lu-PSMA Based Therapies

Phillip Kuo, MD, PhD, University of Arizona

4:55–5:40 pm

Primer for the Radiation Safety Officer, from Patient Release to Waste Management

Michael Sheetz, MS, CHP, DABMP, University of Pittsburgh

5:40-5:50 pm

Question and Answer

5:50–7:00 pm

Reception with Exhibitors

Saturday, October 26

7:30–8:30 am

Breakfast with Exhibitors

THERAPEUTICS IN THE ENDOCRINE SYSTEM

8:30–9:15 am

Updates and Controversies of Radioiodine Theranostic in Differentiated Thyroid Cancer

Douglas Van Nostrand, MD, FACP, FACNM, MedStar Washington Hospital Center

9:15–10:00 am

The Role of I-131 MIBG in the Treatment of Neuroendocrine Cancers

Daniel Pryma, MD, University of Pennsylvania

10:00–10:15 am

Question and Answer

10:15-10:45 am       

Coffee Break with Exhibitors

THERAPEUTICS IN THE GASTROINTESTINAL SYSTEM

10:45–11:30 am

Overview of the Treatment Landscape in Neuroendocrine Malignancies

Christopher Lieu, MD, University of Colorado; Jennifer Kwak, MD, University of Colorado

11:30–11:55 am

Optimizing the Use of 177Lu-Dotatate in Clinical Practice and Cases

Jennifer Kwak, MD, University of Colorado

11:55 am–12:20 pm

Co-Managing the Patient with Metastatic Neuroendocrine Disease

Christopher Lieu, MD, University of Colorado

12:20–12:30 pm

Question and Answer

12:30–1:30 pm

Lunch with Exhibitors

THERAPEUTICS IN THE GENITO-URINARY SYSTEM – PROSTATE CANCER

1:30–2:00 pm

Overview of the Treatment Landscape in Castration-Resistant Prostate Cancer

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

2:00–2:30 pm

The Role of 223Ra-Dichloride

Phillip Koo, MD, Banner MD Anderson Cancer Center

2:30–3:00 pm

Current Status of 177Lu-PSMA Based Therapies and What is Coming Down the Road

Phillip Kuo, MD, PhD, University of Arizona

3:00–3:50 pm

Co-Managing the Patient with Metastatic Castration-Resistant Prostate Cancer

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center; Phillip Koo, MD, Banner MD Anderson Cancer Center; Phillip Kuo, MD, PhD, University of Arizona

3:50–4:00 pm

Question and Answer

4:00–5:00 pm

Reception with Exhibitors

Sunday, October 27

7:30–8:30 am

Breakfast

BILLING AND REGULATORY ISSUES IN THERAPEUTICS

8:30–9:15 am

Coding and Reimbursement in Therapeutics

Denise Merlino, CNMT, CPC, MBA, FSNMMIT, Merlino Health Care Consulting Corp.

9:15–9:45 am

Licensing and regulatory requirements for Targeted Alpha Therapies

Shaemus Gleason, Bayer HealthCare Pharmaceuticals Inc.

9:45–10:00 am

Question and Answer

10:00–10:15 am

Break

10:15–11:00 am

Overview of the Meeting and Roadmap to the Future of Radionuclide Therapy

Phillip Koo, MD, Banner MD Anderson Cancer Center; Daniel Pryma, MD, University of Pennsylvania

11:00–11:30 am

Frequently Asked Questions in Radionuclide Therapy

11:30–11:45 am

Closing Remarks

Phillip Koo, MD, Banner MD Anderson Cancer Center; Daniel Pryma, MD, University of Pennsylvania

11:45 am

Conference Adjourns